Skip to main content
. Author manuscript; available in PMC: 2016 Jan 1.
Published in final edited form as: J Clin Gastroenterol. 2015 Jan;49(1):76–83. doi: 10.1097/MCG.0000000000000055

Figure 1.

Figure 1

Comparison of Global Self-Efficacy (GSE) Scores by Level of Depressive Symptomatology at Baseline (left panel, N=384) and Treatment Week 24 (right panel, N=165). Significance bars represent pairwise comparisons using Kruskal-Wallis test with a Bonferroni correction for multiple comparisons set at 0.05/3=0.0167. Among baseline participants, GSE was highest among those with no depressive symptomatology at baseline when compared to participants with mild-to-moderate (p<0.001) and severe (p<0.001) depressive symptoms, respectively. Among participants who continued on treatment from week 24 to 48, GSE at treatment week 24 was higher among those with no depressive symptoms when compared with those with severe depressive symptoms (p<0.001).